Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Colorcon
Medtronic
Farmers Insurance
US Department of Justice
Mallinckrodt
Federal Trade Commission
McKinsey
Healthtrust

Generated: February 17, 2019

DrugPatentWatch Database Preview

Sandoz Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SANDOZ INC, and what generic alternatives to SANDOZ INC drugs are available?

SANDOZ INC has one hundred and thirty-eight approved drugs.

There are four US patents protecting SANDOZ INC drugs. There are fifteen tentative approvals on SANDOZ INC drugs.

There are twenty patent family members on SANDOZ INC drugs in eighteen countries and one hundred and eighty-two supplementary protection certificates in twelve countries.

Summary for Sandoz Inc

Drugs and US Patents for Sandoz Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz Inc TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE polymyxin b sulfate; trimethoprim sulfate SOLUTION/DROPS;OPHTHALMIC 064211-001 Apr 13, 1998 AT RX No No ➤ Sign Up ➤ Sign Up
Sandoz Inc BUPROPION HYDROCHLORIDE bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 077475-001 Mar 12, 2008 AB2 RX No No ➤ Sign Up ➤ Sign Up
Sandoz Inc ENALAPRIL MALEATE enalapril maleate TABLET;ORAL 075621-003 Aug 22, 2000 DISCN No No ➤ Sign Up ➤ Sign Up
Sandoz Inc PALONOSETRON HYDROCHLORIDE palonosetron hydrochloride INJECTABLE;INTRAVENOUS 202521-001 Oct 13, 2015 AP RX No No ➤ Sign Up ➤ Sign Up
Sandoz Inc TIMOLOL MALEATE timolol maleate SOLUTION/DROPS;OPHTHALMIC 074262-001 Apr 28, 1995 AT1 RX No Yes ➤ Sign Up ➤ Sign Up
Sandoz Inc COSYNTROPIN cosyntropin SOLUTION;INTRAVENOUS 022028-001 Feb 21, 2008 DISCN No No ➤ Sign Up ➤ Sign Up
Sandoz Inc LEVOBUNOLOL HYDROCHLORIDE levobunolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 074850-001 Oct 28, 1996 AT RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Sandoz Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sandoz Inc BETOPTIC betaxolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 019270-001 Aug 30, 1985 4,311,708 ➤ Sign Up
Sandoz Inc ANGIOMAX bivalirudin INJECTABLE;INTRAVENOUS 020873-001 Dec 15, 2000 5,196,404*PED ➤ Sign Up
Sandoz Inc BETOPTIC betaxolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 019270-001 Aug 30, 1985 4,252,984 ➤ Sign Up
Sandoz Inc BETOPTIC betaxolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 019270-001 Aug 30, 1985 4,342,783 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SANDOZ INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Injection 250 mg/vial ➤ Subscribe 2009-09-01

Supplementary Protection Certificates for Sandoz Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/025 United Kingdom ➤ Sign Up PRODUCT NAME: LINEZOLID; REGISTERED: UK PL 00032/0259 20010105; UK PL 00032/0260 20010105; UK PL 00032/0261 20010105; UK PL 00032/0262 20010105
/2014 Austria ➤ Sign Up PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230
2014022 Lithuania ➤ Sign Up PRODUCT NAME: PACLITAXELUM; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
C0022 France ➤ Sign Up PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
C/GB10/031 United Kingdom ➤ Sign Up PRODUCT NAME: SILODOSIN, OPTIONALLY IN A FORM OF A PHARMACEUTICAL ACCEPTABLE SALT; REGISTERED: UK EU/1/09/607/001-014 20100129; UK EU/1/09/608/001-014 20100129
C0019 France ➤ Sign Up PRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGUSTRATION: CH/LI 54 393 19971223
00110 Netherlands ➤ Sign Up PRODUCT NAME: GATIFLOXACINUM, DESGEWENST IN DE VORM VAN EEN HYDRAAT, ZUURADDITIEZOUT OF ALKALISCH ZOUT, IN HET BIJZONDER GATIFLOXACINUM SESQUIHYDRICUM; REGISTRATION NO/DATE: DE 48870.00.00, 48870.01.00, 48872.00.00, 48872.01.00, 48874.00.00, 48874.01.00, 48876.00.00, 48876.01.00 20011022
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
McKesson
UBS
Daiichi Sankyo
Covington
QuintilesIMS
Accenture
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.